As a financial analyst, after analyzing the transcript of the earnings conference call, it is recommended to adopt an 'underweight' investment stance for Baxter International Inc. The company reported a 1% increase in sales on a reported basis, 2% increase in constant currency, and 3% increase operationally in the second quarter, in line with expectations. Adjusted earnings of $0.63 per diluted share exceeded guidance, reflecting solid execution, ongoing impacts from business transformation efforts, and a modest benefit from other income and a lower tax rate.

However, there are some concerning factors to consider. Sales in the Hospital Products business advanced 4% operationally, but sales in the 'other' category declined by 10%. Additionally, sales in the Renal business were up 3% operationally, but the mid-single-digit growth of core hemostats and sealants was more than offset by lower sales of non-core products. The company's updated outlook for 2017 and 2020 includes increased sales growth expectations and adjusted operating margins, but there are still concerns about the impact of cyclophosphamide competition and mix of strategic product exits.

The adjusted operating margin in the second quarter was 16.1%, an improvement of 380 basis points versus the prior year, which is positive. However, it is important to note that transition service income totaled approximately $16 million in the quarter, a reduction of approximately $10 million compared to the second quarter of 2016, and that the company expects transition service incomes to total approximately $20 million in the second half of 2017.

Overall, while there are positive aspects of the company's performance, the concerns around declining sales in certain business segments and the impact of cyclophosphamide competition should be carefully considered when making investment decisions. It is recommended to adopt an 'underweight' investment stance for Baxter International Inc. based on these factors. As always, it is important to continuously monitor and reassess the company's performance and market conditions.